Dimitar Efremov, MD, PhD, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, shares some insights into the future of chronic lymphocytic leukemia (CLL) treatment, drawing focus on novel drug combinations. Dr Efremov first explains the excitement surrounding novel agents that function by blocking microenvironmental signals, such as Bruton's tyrosine kinase (BTK) inhibitors. Dr Efremov then highlights the importance of further investigating combinations with the BCL-2 inhibitor venetoclax, which may allow for deeper clinical responses and improved outcomes for patients with CLL. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.

свернуть